The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.
 
Deirdre J. Cohen
Consulting or Advisory Role - Astellas Pharma
Speakers' Bureau - Guardant Health
Research Funding - Eisai (Inst); Merck (Inst); Viome (Inst)
 
Judith D. Goldberg
No Relationships to Disclose
 
Lawrence P. Leichman
No Relationships to Disclose
 
Tsivia Hochman
No Relationships to Disclose
 
Elliot Newman
No Relationships to Disclose
 
Kevin Lee Du
No Relationships to Disclose
 
Alec Megibow
No Relationships to Disclose
 
Paul Eliezer Oberstein
Consulting or Advisory Role - Amal Therapeutics; AstraZeneca; Ipsen; Janssen Oncology; Loxo/Lilly
Speakers' Bureau - AstraZeneca
Research Funding - Amal Therapeutics (Inst); Arcus Biosciences (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Zai Lab (Inst)
Expert Testimony - Ipsen
Travel, Accommodations, Expenses - Merck
 
Raed Moh'd Taiseer Al-Rajabi
Stock and Other Ownership Interests - Actinium Pharmaceuticals; Seagen
Consulting or Advisory Role - AstraZeneca; Bayer
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lexicon (Inst); Lilly (Inst); Merck (Inst); Sillajen (Inst)
 
Aaron J. Scott
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Consulting or Advisory Role - Exelixis; Pfizer; QED Therapeutics
Research Funding - Exelixis; Five Prime Therapeutics; Genentech; Incyte; Merck
Travel, Accommodations, Expenses - Exelixis; QED Therapeutics
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Wells A. Messersmith
Honoraria - Research to Practice (Inst)
Consulting or Advisory Role - Amgen; Criterium (Inst); QED Therapeutics; Zymeworks
Research Funding - Agenus (Inst); ALX Oncology (Inst); Beigene (Inst); CanBas (Inst); Exelixis (Inst); Experimental Drug Development Centre (EDDC); FATE Therapeutics (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); PureTech (Inst); RasCal (Inst)
 
Colin D. Weekes
Honoraria - Bayer; Celgene; Lilly
Consulting or Advisory Role - Celgene; Ipsen; Merrimack
Research Funding - AstraZeneca; Celgene; Genentech/Roche; Novartis